Striatal D1 Dopamine Neuronal Population Dynamics in a Rat Model of Levodopa-Induced Dyskinesia. 2022

Shasha Gao, and Rui Gao, and Lu Yao, and Jie Feng, and Wanyuan Liu, and Yingqiong Zhou, and Qiongchi Zhang, and Yong Wang, and Jian Liu
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Institute of Neuroscience, Xi'an Jiaotong University Health Science Center, Xi'an, China.

BACKGROUND The pathophysiology of levodopa-induced dyskinesia (LID) in Parkinson's disease (PD) is not well understood. Experimental data from numerous investigations support the idea that aberrant activity of D1 dopamine receptor-positive medium spiny neurons in the striatal direct pathway is associated with LID. However, a direct link between the real-time activity of these striatal neurons and dyskinetic symptoms remains to be established. METHODS We examined the effect of acute levodopa treatment on striatal c-Fos expression in LID using D1-Cre PD rats with dyskinetic symptoms induced by chronic levodopa administration. We studied the real-time dynamics of striatal D1 + neurons during dyskinetic behavior using GCaMP6-based in vivo fiber photometry. We also examined the effects of striatal D1 + neuronal deactivation on dyskinesia in LID rats using optogenetics and chemogenetic methods. RESULTS Striatal D1 + neurons in LID rats showed increased expression of c-Fos, a widely used marker for neuronal activation, following levodopa injection. Fiber photometry revealed synchronized overactivity of striatal D1 + neurons during dyskinetic behavior in LID rats following levodopa administration. Consistent with these observations, optogenetic deactivation of striatal D1 + neurons was sufficient to inhibit most of the dyskinetic behaviors of LID animals. Moreover, chemogenetic inhibition of striatal D1 + neurons delayed the onset of dyskinetic behavior after levodopa administration. CONCLUSIONS Our data demonstrated that aberrant activity of striatal D1 + neuronal population was causally linked with real-time dyskinetic symptoms in LID rats.

UI MeSH Term Description Entries

Related Publications

Shasha Gao, and Rui Gao, and Lu Yao, and Jie Feng, and Wanyuan Liu, and Yingqiong Zhou, and Qiongchi Zhang, and Yong Wang, and Jian Liu
January 2005, Annals of neurology,
Shasha Gao, and Rui Gao, and Lu Yao, and Jie Feng, and Wanyuan Liu, and Yingqiong Zhou, and Qiongchi Zhang, and Yong Wang, and Jian Liu
December 2018, The Journal of pharmacology and experimental therapeutics,
Shasha Gao, and Rui Gao, and Lu Yao, and Jie Feng, and Wanyuan Liu, and Yingqiong Zhou, and Qiongchi Zhang, and Yong Wang, and Jian Liu
June 2005, Parkinsonism & related disorders,
Shasha Gao, and Rui Gao, and Lu Yao, and Jie Feng, and Wanyuan Liu, and Yingqiong Zhou, and Qiongchi Zhang, and Yong Wang, and Jian Liu
March 2009, Proceedings of the National Academy of Sciences of the United States of America,
Shasha Gao, and Rui Gao, and Lu Yao, and Jie Feng, and Wanyuan Liu, and Yingqiong Zhou, and Qiongchi Zhang, and Yong Wang, and Jian Liu
February 2018, Neuron,
Shasha Gao, and Rui Gao, and Lu Yao, and Jie Feng, and Wanyuan Liu, and Yingqiong Zhou, and Qiongchi Zhang, and Yong Wang, and Jian Liu
October 2007, Biological psychiatry,
Shasha Gao, and Rui Gao, and Lu Yao, and Jie Feng, and Wanyuan Liu, and Yingqiong Zhou, and Qiongchi Zhang, and Yong Wang, and Jian Liu
April 2020, The Journal of neuroscience : the official journal of the Society for Neuroscience,
Shasha Gao, and Rui Gao, and Lu Yao, and Jie Feng, and Wanyuan Liu, and Yingqiong Zhou, and Qiongchi Zhang, and Yong Wang, and Jian Liu
July 2008, Journal of neurochemistry,
Shasha Gao, and Rui Gao, and Lu Yao, and Jie Feng, and Wanyuan Liu, and Yingqiong Zhou, and Qiongchi Zhang, and Yong Wang, and Jian Liu
April 2000, Annals of neurology,
Shasha Gao, and Rui Gao, and Lu Yao, and Jie Feng, and Wanyuan Liu, and Yingqiong Zhou, and Qiongchi Zhang, and Yong Wang, and Jian Liu
June 2018, Cell reports,
Copied contents to your clipboard!